Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

Abstract Background Decisions regarding maintenance therapy in patients with multiple myeloma should be based on both treatment efficacy and health-related quality of life (HRQL) consequences. In the CARFI trial, patients with first relapse of multiple myeloma underwent salvage autologous stem cell...

Full description

Bibliographic Details
Main Authors: Lene Kongsgaard Nielsen, Fredrik Schjesvold, Sören Möller, Nina Guldbrandsen, Markus Hansson, Kari Remes, Valdas Peceliunas, Niels Abildgaard, Henrik Gregersen, Madeleine T. King
Format: Article
Language:English
Published: SpringerOpen 2024-02-01
Series:Journal of Patient-Reported Outcomes
Subjects:
Randomized clinical trial
Multiple myeloma
Health-related quality of life
Carfilzomib
Online Access:https://doi.org/10.1186/s41687-024-00691-2

Internet

https://doi.org/10.1186/s41687-024-00691-2

Similar Items